Trellus Health Share Discussion Threads

[cambridgedon] 03/10/2022 18:02

Good presentation.
The Dr seems v impressive.
I added on Friday at 7.2p so well pleased.
CD

[mikemine1] 03/10/2022 17:57

I don't know how you guys get to the presentations. I've been all over Trellus's website and zilch. Got a link anybody?

[wan] 03/10/2022 16:44

An excellent webinar presentation, with the CEO exuding a high degree of knowledge, and importantly confidence in terms of delivery. And so it would appear that we can expect news flow accordingly.

Thus, it is justifiable to repeat, that with the changes made, including to the overall strategy, it's already having a positive effect and impact, and looks set to be transformative.

[wan] 30/9/2022 12:42

I have not got access to the full note -

Cash runway extended, multiple near term opps
Trellus Health PLC (TRLS:LON) | 7.2 -0.1 (-9.4%) | Mkt Cap: 11.7m

The incoming new management team at Trellus has acted swiftly to reduce cash burn, extending the runway to early 2025. The company is now transitioning to a revenue-generating business, with the first paying members enrolled post-period end and multiple near term commercial opportunities across its D2C and B2B2C offerings in the advanced stages of finalisation. These should unlock access to substantial patient populations, accelerating adoption of the platform, commercialisation and, ultimately, shareholder value.

[jane deer] 30/9/2022 10:59

Agree that valuation is low (below 2022F net cash) as there are >2 years’ runway for company to show some traction. So even if you only value the company as an option, it is a reasonably long-dated option.

Getting Dr Dubinsky into the CEO seat will surely increase the company’s credibility. Yet it is amazing how far off-track Trellus has gone in the last few months. On the May ImC call, then-CFO stated that the company would be profitable on a run-rate basis by end-23 and Singer was forecasting revenue of $11m (already cut from $18m) in 2023. Today, I see Singer has removed its 2023 forecasts, citing a lack of visibility.

[btgman] 30/9/2022 08:15

Insane valuation one to add to over the coming months even in this market

AIMHO
GLA
BTG

[dealer55] 30/9/2022 07:47

Agree unusual that small caps have cash and a rosey future with MCAP under cash. I’d say this should be 30-40p priced fairly.

[wan] 30/9/2022 07:43

Toady's Results highlight numerous and highly encouraging developments and provides a backdrop of very positive outlook and commentary.

Cash at the end of June equates to circa £21m and will last through and into 2025, and when compared to the current market cap of £13m, even the current cash outweighs the market cap by a significant margin!

It would appear the changes made, including to the overall strategy, is already having a positive impact, and looks set to be transformative.

[wan] 18/9/2022 09:41

Context - Gastroenterology is a key (top) business area for Takeda, with recently reported revenues of $1.8bn (270.4 billion yen) in their recent first quarter results -


Gastroenterology includes the management of inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.

Trellus health - Customized resilience roadmaps developed by experts, delivered by technology and, designed by a team dedicated to promoting health and wellness for people living with chronic conditions, starting with inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. The Trellus Approach is based on a scientifically validated method developed at the Mount Sinai Health System to improve one’s strength and confidence in managing a chronic condition, and ability to overcome adversity while dramatically improving outcomes at reduced cost.

The TrellusElevate™ Platform and mobile app connects the team, the tools and the technology needed to ensure all people living with a chronic condition have hope and thrive.

Part of the Trellus Health offering for healthcare providers and individuals includes medication adherence and the importance of disease monitoring, with a strategy to focus on both a Direct To Consumer model as well as a Business-to-Business model to expand their customer base, and to add further regional and national multi-year contracts with payers from 2023 onwards -


Readers will already appreciate that Dr Marla Dubinsky is a Trellus Health co-founder and became the CEO in July 2022.

The following recently caught my attention -

September 14, 2022

Prometheus Laboratories Announces Partnership with Takeda to Launch CDPATH™, a Personalized Prognostic Tool Advancing Innovation for Crohn’s Disease Patients

SAN DIEGO, Sept. 14, 2022 /PRNewswire/ -- Prometheus Laboratories Inc. ("Prometheus") today announced its partnership with Takeda Pharmaceutical Company Limited ("Takeda") to nationally launch CDPATH, an innovative prognostic tool for Crohn's disease (CD) patients. CDPATH is a personalized risk assessment tool that can be used in combination with a physician's clinical assessment to evaluate an adult patient's risk for developing serious complications of CD such as bowel strictures, internal penetrating disease, or non-perianal surgery within three years.

The CDPATH test is a result of a collaboration among Prometheus, MiTest Health LLC ("MiTest") and Takeda Pharmaceutical Company Limited ("Takeda"). MiTest defined and established the clinical relevance of the CDPATH model through an independent clinical study. Prometheus, a CLIA certified and CAP accredited laboratory, validated CDPATH and is the processing laboratory for the CDPATH program. Takeda will make CDPATH available for use by US-based physicians and offer the test free of charge to eligible patients, with the goal of supporting shared decision-making between patients and healthcare providers.

"This tool was developed to address a significant unmet need in the management of Crohn's disease," said Dr. Marla Dubinsky, who along with being a Co-inventor and Co-founder of MiTest Health, is also a Professor of Pediatrics and Medicine at the Icahn School of Medicine, Chief of Division of Pediatric Gastroenterology and Co-director of the Mount Sinai Susan and Leonard Feinstein IBD Clinical Center. "With CDPATH, we want to identify patients before they have severe disease and inform discussions with patients about the management of disease."

This partnership with Takeda, a pharmaceutical industry leader in the field of gastroenterology (GI), contributes to the Prometheus mission of enabling precision-guided patient care and improving disease outcomes.

Mike Walther, President of Prometheus Laboratories commented, "We are pleased to partner with Takeda to make CDPATH available to healthcare providers and their patients. Supporting the launch of CDPATH is yet another milestone among our strategic initiatives as we continue to provide innovative clinical lab services to guide care from disease interception through therapeutic optimization and monitoring."

"At Takeda, we are driven by the challenge of making a meaningful difference in the lives of patients with inflammatory bowel disease, and working with partners to provide solutions that can help transform their care," said Gamze Yüceland, Head, Gastroenterology Business Unit, Takeda Pharmaceuticals, U.S.A., Inc. "Offering CDPATH free of charge to eligible CD patients will help deliver an innovative tool to the community that can help inform and personalize CD management."

About CDPATH
CDPATH integrates patient-specific serologic markers and genetic marker status, identified via a blood sample, with patient's CD characteristics to help predict a low, medium, and high risk for potentially developing serious CD complications over a three-year period. It is intended to be used in combination with a physician's clinical assessment. Healthcare providers will receive a CDPATH test report with a graphical risk profile that can then be used to facilitate discussions with patients.

CDPATH is only validated in, and can only be performed on, adult Crohn's disease patients (≥18 years old) diagnosed within the past ten (10) years, who have not experienced a Crohn's disease complication such as bowel strictures, internal penetrating disease, or non-perianal surgery (bowel resection or stricturoplasty).

CLIA: Clinical Laboratory Improvement Amendments; CAP: College of American Pathology

Dr. Dubinsky is co-founder and equity owner in a MiTest Health, which received a licensing fee from Takeda for CDPATH. Dr. Dubinsky has received compensation from both Takeda Pharmaceutical and Prometheus Laboratories as a consultant. In addition to Takeda, Dr. Dubinsky also serves as a paid consultant for other pharmaceutical companies that develop and/or manufacture treatments for inflammatory bowel disease (IBD). Dr. Dubinsky is co-founder and equity owner of two start-up companies involved in IBD healthcare, Trellus Health and GoDoRun.

Full release -

An interesting development, connections, and provides food for thought!

[senttothegallows] 07/9/2022 09:16

This will be snapped up IMHO

[wan] 07/9/2022 09:11

By my estimates, the market cap is still currently worth less than the cash element, even with todays notable share price improvement.

[wan] 31/8/2022 07:30

Over 11m shares traded in Trellus Health yesterday, which was a higher trade volume than in Legal & General!

One would assume that there will be accompanying holding announcements in due course, and perhaps something more. Time will tell.

[faz] 30/8/2022 07:32

At 7p mdown from 70p a passive investor will need a return of 10 times to get back what they invested, just to be flat. Anyone subscribing to the fundraise in May would have lost over 80% of their investment. Like Renalytix there appears to be no business acuman behind the idea and like Renalyix the stock market has been used as a money-raid and for no other reason.

[wan] 27/8/2022 04:22

And I note a larger jump in volume yesterday.

[wan] 24/8/2022 17:11

Notable volume today.

[wan] 13/8/2022 11:26

I also meant to add that EKF indicated their intention to launch a Calprotectin test this year. Fecal calprotectin (or faecal in the UK), is a marker of mucosal inflammation. The test can help physicians diagnose inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and differentiate them from irritable bowel syndrome (IBS).

Going forwards, Trellus intend to also address IBS, and I note a test for this is included in the indicated list of tests at EKF owned ADL Health laboratory in the US.

[wan] 13/8/2022 11:06

I note recently that some large players are actively interested or indeed already moving into the area of addressing chronic conditions.

I also note the following -

Congratulations from the entire Trellus community to our co-founder, Dr. Laurie Keefer for receiving the Distinguished Investigator Award for Women in Neurogastroenterology -

Recall that in September 2021 Trellus signed an agreement to provide an Inflammatory Bowel Disease ("IBD") demonstration programme for the Mount Sinai Health System.

Following enrolment, the demonstration programme will coordinate six months of active care management followed by a final programme report, expected to be available within 30 days of programme completion. This initial demonstration programme is expected to commence before the end of 2021 with conclusions from the final programme report expected in 2022.

One would assume that that final programme report must be getting quite close to publication.

[wan] 01/8/2022 07:51

Trellus not intending to sit on their laurels either though with todays announcement.

[wan] 30/7/2022 05:30

I note the large volume yesterday.

[wan] 27/7/2022 10:34

Edit to the above post - In short, it takes time to build up capabilities and develop technology, but it's easier and faster to acquire (or strategically partner with) those who now look attractively affordable. Hence, it's likely we will see M&A activity heat up accordingly going forwards.

[wan] 27/7/2022 10:24

I would also add that the market backdrop has resulted in many valuations being significantly reduced, and will mean that affected companies, especially those such as Trellus with 'scientifically validated' methods delivered by technology, are likely to come on to certain radars.

In Trellus's case, there is the potential from companies looking to pivot, or pivot further, into chronic disease management, either via partnering or acquisition.

In short, it takes time to build up capabilities and develop technology, but it's easier and faster to acquire (or strategically partner with) those who now look attractively affordable. Hence, it's likely we will see M&A activity heat up accordingly going forwards.

[wan] 27/7/2022 09:14

Cambridgedon...As I allude to in post 211, it looks predominantly like a cash burn reduction exercise and a reflection of who can effectively lead Trellus in the current market, and perhaps more passionately lead and effectively deliver on the strategy, given the new CEO is a co-founder and has unrivalled expertise and reputation in Trellus Health's 'initial' market focus.

We may get further clarification in Interim Results ended June 30th 2022.

[cambridgedon] 26/7/2022 16:08

Does anyone know/have a theory as to why Monique Fayad went??
The share price has certainly bombed since the announcement.
CD

[wan] 22/7/2022 09:11

By my estimates, the shares are currently worth considerably less than the cash element i.e. cash is likely to be currently north of £20m and with a market cap under £15m.

And one assumes, due to the recent announcement, that cash burn, which had already been carefully managed, has been further reduced.

Although I am not sure what the prospects offer given those cut backs and indeed the market backdrop etc.

[senttothegallows] 22/7/2022 08:27

24p of shares traded market cap dropped by 5% over £800,000 corruption IMHO